The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has argenex SE (ARGX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

argenex SE is one of 913 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. argenex SE is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for ARGX's full-year earnings has moved 12.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

Our latest available data shows that ARGX has returned about 3.7% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.8% on a year-to-date basis. This means that argenex SE is outperforming the sector as a whole this year.

One other Medical stock that has outperformed the sector so far this year is Agilent Technologies (A). The stock is up 3.3% year-to-date.

The consensus estimate for Agilent Technologies' current year EPS has increased 1.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

Looking more specifically, argenex SE belongs to the Medical - Biomedical and Genetics industry, which includes 438 individual stocks and currently sits at #92 in the Zacks Industry Rank. On average, this group has gained an average of 3.6% so far this year, meaning that ARGX is performing better in terms of year-to-date returns.

Agilent Technologies, however, belongs to the Medical - Products industry. Currently, this 84-stock industry is ranked #160. The industry has moved -17% so far this year.

Investors with an interest in Medical stocks should continue to track argenex SE and Agilent Technologies. These stocks will be looking to continue their solid performance.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

argenex SE (ARGX): Free Stock Analysis Report

 

Agilent Technologies, Inc. (A): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research